Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/184269
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUrraza-Robledo, Arguiñe Ivonne-
dc.contributor.authorGiralt i Oms, Marta-
dc.contributor.authorGonzález-Galarza, Faviel Francisco-
dc.contributor.authorVillarroya i Gombau, Francesc-
dc.contributor.authorMiranda Pérez, Alberto Alejandro-
dc.contributor.authorRuiz Flores, Pablo-
dc.contributor.authorGutiérrez Pérez, María Elena-
dc.contributor.authorDomingo, Pere (Domingo Pedrol)-
dc.contributor.authorLópez-Márquez Francisco Carlos-
dc.date.accessioned2022-03-21T15:04:58Z-
dc.date.available2022-03-21T15:04:58Z-
dc.date.issued2021-05-21-
dc.identifier.issn1932-6203-
dc.identifier.urihttp://hdl.handle.net/2445/184269-
dc.description.abstractAntiretroviral therapy has significantly improved prognosis in treatment against HIV infection, however, prolonged exposure is associated to cardiovascular diseases, lipodystrophy, type 2 diabetes, insulin resistance, metabolic alteration, as obesity which includes the accumulation of oxidative stress in adipose tissue. FGF21 is a peptide hormone that is known to regulate glucose and lipid metabolism. FGF21 is expressed and secreted primarily in the liver and adipose tissue, promoting oxidation of glucose/fatty acids and insulin sensitivity. Alterations in FGF21 may be associated with the development of insulin resistance, metabolic syndrome and cardiovascular disease. We hypothesized that FGF21 protein levels are associated with metabolic abnormalities, placing special attention to the alterations in relation to the concurrence of overweight/obesity in people living with HIV (PLWH).-
dc.format.extent12 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherPublic Library of Science (PLoS)-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0252144-
dc.relation.ispartofPLoS One, 2021, vol. 16, num. 5, p. e0252144-
dc.relation.urihttps://doi.org/10.1371/journal.pone.0252144-
dc.rightscc-by (c) Urraza-Robledo, Arguiñe Ivonne et al., 2021-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Bioquímica i Biomedicina Molecular)-
dc.subject.classificationInfeccions per VIH-
dc.subject.classificationHormones peptídiques-
dc.subject.otherHIV infections-
dc.subject.otherPeptide hormones-
dc.titleFGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH).-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec715854-
dc.date.updated2022-03-21T15:04:58Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
715854.pdf688.34 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons